Asset Details
Do you wish to reserve the book?
Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries
Do you wish to request the book?
Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries
2000
Overview
Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons aged ≥65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from ∼11,000 to ∼33,000 European currency units (ecu) per quality-adjusted life year (QALY). Assuming a common incidence (50 cases per 100,000) and mortality rate (20%-40%) for invasive disease, the cost-effectiveness ratios were <12,000 ecu per QALY in all 5 countries. For preventing pneumococcal pneumonia, vaccinating all elderly persons would be highly cost-effective to cost saving. Public health authorities should consider policies for encouraging pneumococcal vaccination for all persons aged ≥65 years.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
/ Biological and medical sciences
/ Humans
/ Pneumococcal Vaccines - administration & dosage
/ Pneumococcal Vaccines - economics
/ Pneumococcal Vaccines - immunology
/ Pneumonia, Pneumococcal - epidemiology
/ Pneumonia, Pneumococcal - mortality
/ Pneumonia, Pneumococcal - prevention & control
/ Staphylococcal infections, streptococcal infections, pneumococcal infections
